JD Health International, Inc.
37.60
HKD
-0.38
(-1.00%)
JD Health International, Inc.
HKEX:6618
(Hong Kong Exchange)
Recent
price
37.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- JD Health International Inc. operates as a technology-driven online healthcare platform and retail pharmacy company primarily serving the Chinese market. The company’s core products and services include pharmaceutical and healthcare product sales; online consultation and prescription renewal; chronic disease management; family doctor services; consumer healthcare products; home care services such as wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; smart healthcare and digital health solutions; smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device setup and support including blood glucose meters and oxygen generators; rapid testing products; and online marketing services targeted at advertisers. Its retail pharmacy business operates through direct sales, an online marketplace, and an omnichannel model. The company also offers a platform for doctors to practice multisite, manage patients, conduct healthcare research, and exchange academic and clinical knowledge. JD Health strategically focuses on integrating pharmaceutical supply chain services with comprehensive healthcare offerings across user lifespans. Its geographic operations include extensive reach within China, supported by a strong logistics network enabling market-leading 24-hour prescription delivery. Founded in 2018, JD Health is headquartered in Beijing, China and functions as the healthcare unit of JD.com. In the past 1-2 years, JD Health has pursued multiple strategic partnerships and expansions. Notably, it forged a strategic cooperation agreement with Boehringer Ingelheim Animal Health to leverage pharmaceutical supply chain strength for pet healthcare services. It also announced a strategic partnership with INTCO Medical to co-develop high-end customized medical products via a Customer-to-Manufacturer model, aiming to innovate medical protection ecosystems and enhance user safety and convenience. These partnerships underline JD Health’s commitment to expanding product innovation and accelerating growth in trending healthcare products. Additionally, JD Health has actively expanded offline pharmacy networks to digitize traditional brick-and-mortar pharmacies. The company continuously enhances its digital health and e-commerce capabilities, reinforcing its position in China’s rapidly growing online healthcare and retail pharmacy sectors. Overall, JD Health International Inc. combines online pharmaceutical retail, healthcare services, digital health technologies, and strategic industry partnerships to serve consumer and professional healthcare markets within China, emphasizing innovation and comprehensive service offerings across healthcare verticals. This description integrates the company’s detailed product and service portfolio, geographic and business scope, and noteworthy recent corporate developments and strategic alliances up to 2025.
Company News
JD Health International Inc. (JDHIY) Q4 2025 Earnings Call Transcript
JD Health International Inc. (JDHIF) Q2 2025 Earnings Call Transcript
JD Health International Inc. (JDHIF) Q4 2024 Earnings Call Transcript
JD Health: Becoming Bullish On Tailwinds And Catalysts (Rating Upgrade)
JD Health International Inc. (JDHIF) Q4 2023 Earnings Call Transcript
Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher
JD Health International Inc. (JDHIF) Q4 2022 Earnings Call Transcript